Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00577850 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetics of a Single 14C-labeled Dose of Risedronate or Alendronate Followed by Once-a-week Unlabeled Oral Dose
A Phase 1 study of Osteoporosis and Osteopenia, sponsored by Warner Chilcott.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
- 2
- Study locations
NCT00577850: Completed Phase 1 study of Osteoporosis and Osteopenia, sponsored by Warner Chilcott.
NCT00577850 is a Phase 1 study of Osteoporosis and Osteopenia that has completed, run by Warner Chilcott. The registered enrollment target is 32 participants, below the 1,546-participant average among 84 other Osteoporosis trials with a reported enrollment target (98% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00577850, a Phase 1 study of Osteoporosis and Osteopenia, has completed, sponsored by Warner Chilcott.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
- 2
- Study locations
Study Summary
The primary objective of this study is to compare the urinary excretion of 14C-labeled risedronate and alendronate over 28 days.
Conditions Studied
Interventions
- DRUG alendronate
- DRUG risedronate
Study Locations (2)
Florida
- Research Facility - Gainesville
Louisiana
- Research Site - New Orleans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2002-11 |
| Est. Completion | 2004-02 |
| Phase | Phase 1 |
What the finished NCT00577850 record still lists
NCT00577850 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 1,546-participant average among 84 other Osteoporosis trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with Osteoporosis appearing as the primary indexed condition, and to 2 interventions - of which alendronate is the first listed.
NCT00577850 reports a single indexed study location in Florida, Louisiana.
Frequently Asked Questions
What is clinical trial NCT00577850 about?
NCT00577850 is a clinical study titled "Pharmacokinetics of a Single 14C-labeled Dose of Risedronate or Alendronate Followed by Once-a-week Unlabeled Oral Dose". The primary objective of this study is to compare the urinary excretion of 14C-labeled risedronate and alendronate over 28 days.
What is the current status of trial NCT00577850?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2002-11. Estimated completion is 2004-02.
What conditions does trial NCT00577850 study?
This clinical trial studies the following conditions: Osteoporosis, Osteopenia.
What interventions are being tested in trial NCT00577850?
The interventions under investigation include: alendronate (DRUG), risedronate (DRUG).
Who is sponsoring clinical trial NCT00577850?
This trial is sponsored by Warner Chilcott, which has 53 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00577850 being conducted?
This trial has 2 study locations across Florida, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteoporosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00577850's enrollment target sits among peer trials
32 68th of 84 higher than 17 of 84 other Osteoporosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Osteoporosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Romosozumab in Women With Multiple Myeloma and Osteoporosis
ACTIVE NOT RECRUITING · Phase 1
-
Patient- and Physician-Based Osteoporosis Education
COMPLETED · Phase 1
-
Assess Bioequivalence of One 150 mg Risedronate Tablet Versus Two 75 mg Risedronate Tablets in Healthy Subjects
COMPLETED · Phase 1
-
Improving Bone Health in Adolescent Girls: The Youth Osteoporosis and Understanding Total Health (YOUTH) Study
COMPLETED · Phase 1
-
A Safety, Tolerability and Pharmacodynamics Study of ACE-011 (ActRIIA-IgG1) in Healthy Postmenopausal Women
COMPLETED · Phase 1
-
A Comparison Study of PF708 and Forteo in Healthy Subjects
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia